Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, November 11 at 2:00 PM ET

Register Free →

Calcium Trisodium Pentetate (Ca-DTPA) ampoules

Open
W6369-27-A062International

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The Department of National Defence, through the Strategic Medical Countermeasures Program on behalf of the Canadian Forces Health Services Group, is seeking the supply of Calcium Trisodium Pentetate (Ca-DTPA) ampoules to treat Canadian Armed Forces personnel exposed to radioactive contamination involving transuranic elements. The required product must be a sterile solution for intravenous injection containing 1,000 mg to 1,055 mg of active ingredient in a 5 mL ampoule, with a minimum shelf-life of 36 months from the date of manufacture. To ensure consistency with existing stockpiles, the product must adhere to specific packaging and labelling requirements and hold valid marketing authorization from Health Canada, the FDA, the EMA, or an EU member state. The procurement is being conducted via an Advance Contract Award Notice, with Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG identified as the sole known supplier capable of meeting the technical and clinical requirements. The contract is anticipated to run from the award date until March 31, 2031, with an estimated total value of 47,500 CAD. The firm requirement consists of 750 ampoules delivered in three annual increments of 250, starting no later than March 1, 2027, and ending by March 1, 2029. Additionally, the contract includes an option for up to 500 more ampoules exercisable throughout the contract period. This procurement is subject to the Canadian Free Trade Agreement and is not subject to set-asides or the Procurement Strategy for Indigenous Business.

General Info

DND seeks 750-1,250 Ca-DTPA ampoules for radioactive contamination treatment through 2031.

Documents

1
PDF, High priority: read this firstpresolicitation
High

AI Contract Breakdown

Uniform Contract Format

Sign up to view the full breakdown with detailed analysis of each section.

Timeline

PhasePresolicitation
Posted

Solicitation

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Get full access to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyGovernment of Canada → Department of National Defence
Contacts1 person available
OfficeN/A
Office AddressN/A
Contacts
Eduardo VidesContracting Authority

Full Description

Show more
NOTICE OF PROPOSED PROCUREMENT The Department of National Defence (DND), through the Strategic Medical Countermeasures Program (SMCP) on behalf of the Canadian Forces Health Services Group (CF H Svcs Gp), has a requirement for the supply of Calcium Trisodium Pentetate (Ca-DTPA) ampoules for the treatment of Canadian Armed Forces (CAF) personnel who may have been exposed to radioactive contamination involving transuranic elements. The Ca-DTPA product must consist of sterile Calcium Trisodium Pentetate solution for injection, containing approximately 1,000 mg to 1,055 mg of active ingredient in a 5 mL ampoule suitable for intravenous administration. The product is intended for use as a medical countermeasure to enhance the elimination of internally deposited radioactive transuranic elements, including plutonium, americium and curium, following confirmed or suspected radiological exposure. The product must meet all applicable regulatory, quality assurance, packaging, labelling and shelf-life requirements specified in the solicitation documents. The initial requirement consists of the supply of 250 Ca-DTPA ampoules for delivery no later than 1 March 2027. The resulting contract is anticipated to be valid from contract award date to 31 March 2031 and includes additional scheduled deliveries of 250 ampoules in Fiscal Year 2027-2028 and 250 ampoules in Fiscal Year 2028-2029. The contract will also include an option for up to an additional 500 ampoules exercisable during the contract period. This procurement will be conducted through an Advance Contract Award Notice (ACAN). The Government of Canada has identified Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG as the only supplier currently known to satisfy the operational, clinical and technical requirements associated with this requirement. Suppliers that consider themselves fully qualified and capable of meeting the complete requirement may submit a Statement of Capabilities during the posting period. The Crown retains the rights to negotiate with suppliers on any procurement. Documents may be submitted in either official language of Canada. Barring any applicable trade agreement exceptions or other legal restrictions, eligible suppliers may participate in this solicitation process. NOTE TO SUPPLIERS: Procurement Assistance Canada offers seminars to businesses interested in learning how to sell goods and services to the Government of Canada. These seminars are provided free of charge.

Similar Contracts

Same NAICS industry code

NAICS: 325412
New
DIBBS
BISMUTH SUBSALICYLATE
Solicitation # SPE2DP-27-T-0266
This solicitation, issued by the Defense Logistics Agency (DLA) under number SPE2DP-27-T-0266, is a small business set-aside for the procurement of 55 packages of over-the-counter, sugar-free Bismuth Subsalicylate tablets. Each tablet must contain 262 mg of Bismuth Subsalicylate and 140 mg of Calcium, with each unit of issue consisting of 48 individually sealed tablets. The product has a total shelf life of 36 months, and a minimum of 31 months must remain at the time of receipt by the first government activity. To maintain product integrity, the supplies must be protected from excessive heat exceeding 104 degrees Fahrenheit or 40 degrees Celsius. The contract specifies that packaging and packing must be commercial, with each unit in a sealed container and shipped in suitable commercial exterior containers to ensure safe delivery. Marking and labeling must adhere to Medical Marking Standard No. 1, which supersedes MIL-STD-129, and preservation must follow MIL-STD-2073-1E. Delivery is required FOB Destination to the DC ARNG MED DET in Washington, DC, with a delivery lead time of 20 days. Inspection and acceptance will occur at the destination. The procurement incorporates various FAR and DFARS clauses, including requirements for safeguarding covered defense information, NIST SP 800-171 assessment, and the Buy American Act. Invoicing must be processed electronically through the Wide Area Workflow system.
MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

1 day ago

DEADLINE

in 6 days
View Details

More opportunities from Government of Canada → Department of National Defence

Same awarding agency

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS